Quick Access

SNCB Knockout HAP1 Cell Line

SNCB Knockout HAP1 Cell Line

SNCB Knockout HAP1 Cell Line is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performotion Cas9 Protein and Hassle-Free Cell Selection.

Cat. No EDC08055
Species Human
Cell Line HAP1
Gene SNCB
Size 1×10⁶cells

Product Details

Cat.No. EDC08055 Product Name SNCB Knockout HAP1 Cell Line
Species Human Cell Line HAP1
Cellosaurus ID CVCL_0F62 NCBI Gene ID
Cell Line Synonyms Highly Aggressively Proliferating Immortalized Gene
Summary
This gene encodes a member of a small family of proteins that inhibit phospholipase D2 and may function in neuronal plasticity. The encoded protein is abundant in lesions of patients with Alzheimer disease. A mutation in this gene was found in individuals with dementia with Lewy bodies. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]
Digestion Time 2 min
Morphology Adherent Passage Ratio 1:8~1:10
Complete Culture Medium IMDM+10%FBS Freezing Medium 90%FBS+10%DMSO
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.

FAQ

The choice depends on whether you are studying β-synuclein's role as a presynaptic protein or its emerging functions in modulating α-synuclein aggregation in neurodegenerative disease contexts. The Knockout line is appropriate for asking whether β-synuclein is required for specific cellular phenotypes, but note that physiological β-synuclein function is principally in neurons — HAP1 is most informative for biochemical and interactome studies. Overexpression is useful for studying β-synuclein's reported neuroprotective effect against α-synuclein toxicity in heterologous expression contexts. For synuclein research, the EDITGENE SNCB Knockout in HAP1 is most useful for in vitro biochemistry and rescue with engineered β-synuclein variants in a clean genetic background. For neurodegenerative disease modeling, neuronal cell systems (SH-SY5Y, H4, primary neurons) are more appropriate. Rescue with wild-type or aggregation-promoting variants enables mechanistic dissection.
Yes. β-synuclein rescue experiments require attention to its small protein architecture: • Construct design: use a codon-modified SNCB sequence with a small N-terminal tag (HA, FLAG); C-terminal tags can interfere with the highly acidic C-terminus that mediates protein-protein interactions. • Membrane binding-deficient rescue: N-terminal amphipathic α-helix mutations affecting membrane binding can dissect membrane-associated versus cytosolic functions. • α-synuclein interaction studies: rescue followed by co-expression with α-synuclein enables direct study of β-synuclein's reported neuroprotective interaction. • Disease variant rescue: V70M and P123H variants associated with dementia with Lewy bodies enable disease modeling. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Contact Us
*
*
*
How did you hear about us: